Advanced Oncotherapy (AVO) – Investor presentation and Update

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, will be hosting investor and analyst presentations in London later today and in Zürich, Switzerland, the following day, Tuesday 7 March 2017. The presentations will outline some of the key aspects of Advanced Oncotherapy’s technology, the clinical benefits of proton therapy, the rationale […]

Advanced Oncotherapy (AVO) – Conversion of convertible loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share […]

Advanced Oncotherapy (AVO) – Update on financing and Harley Street building work update

Advanced Oncotherapy (AVO), the developer of next generation proton therapy systems for cancer treatment, announces that further to the financing agreement with Bracknor announced on 22 February 2017, the first tranche has been drawn down by the Company and the initial funds of £1.3 million received (less 5%, in accordance with terms for receipt of […]

Advanced Oncotherapy (AVO) – Financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces it has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm. The Agreement gives the Company the ability to issue a minimum of £13 million in convertible loan notes (Minimum […]

Advanced Oncotherapy (AVO) – Investor Presentations

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it will be hosting investor and analyst presentations in London on Monday 6 March 2017 and in  Zürich, Switzerland the following day, Tuesday 7 March 2017. The presentations will outline some of the key aspects of Advanced Oncotherapy’s […]

Advanced Oncotherapy (AVO) strengthens its board – Daily Telegraph

From Daily Telegraph – StockMarket Wire Advanced Oncotherapy has appointed Dr Nick Plowman as a non-executive director with immediate effect. Plowman is senior clinical oncologist at St Bartholomew’s Hospital and the Hospital for Sick Children at Great Ormond Street in London. Executive chairman Michael Sinclair said: “Dr Plowman has been a welcome source of expert […]

Brand CEO Alan Green talks Advanced Oncotherapy (AVO), Conviviality (CVR), Safestyle (SFE) & Asiamet (ARS) on VOX Markets podcast

<iframe class="wp-embedded-content" sandbox="allow-scripts" security="restricted" width="480" height="300" frameborder="0" scrolling="no" src="//embeds.audioboom slimming pills that work.com/posts/5592554-707-zenith-energy-zen-the-peoples-operator-tpop-plus-russ-mould-alan-green/embed/v4?eid=AQAAAO2xnVjqVVUA#?secret=PUxVeJDHHI” data-secret=”PUxVeJDHHI” title=”audioBoom player”> Brand CEO Alan Green discusses Advanced Oncotherapy (AVO), Conviviality (CVR), Safestyle (SFE) & Asiamet (ARS) with Justin Waite on the VOX Markets podcast. The interview starts at 37 minutes 7 seconds.

Advanced Oncotherapy (AVO) – Appoints Dr Nick Plowman as Non-Executive Director

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Dr Nick Plowman, Senior Clinical Oncologist at St Bartholomew’s Hospital (“Barts”) and the Hospital for Sick Children at Great Ormond Street (“GOSH”) in London, as a Non-Executive Director with immediate effect. Dr Nick Plowman is the UK’s […]

Advanced Oncotherapy (AVO) – Significant Shareholder

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 that Dr Nick Plowman, Chairman of the Company’s medical advisory board, became a significant shareholder on 6 June 2016 and, following subsequent share purchases, currently holds 2,636,799 ordinary shares of 25 pence each in […]